Trial · NCT02289755
Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
NCT02289755, Phase 2, Completed, Allena Pharmaceuticals; results first posted 2016-04-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria. Trials, record NCT02289755. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02289755
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
- NCT number
- NCT02289755
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 16 participants, actual
- Lead sponsor
- Allena Pharmaceuticals
- Conditions
- Hyperoxaluria, Nephrolithiasis
- Interventions
- ALLN-177
- First posted
- 2014-11-13
- Last updated
- 2019-06-05
- Results first posted
- 2016-04-27
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline Period to Treatment Period 24-hour Urinary Oxalate Excretion | 7 days | Change from Baseline is defined as Baseline value (average of Days 2 and 3) minus ALLN-177 treatment value (mean of Days 5, 6, and 7). |
| Secondary | Percent Change From Baseline Period to Treatment Period in 24-hour Urinary Oxalate Excretion | 7 days | Percent Change from Baseline is defined as baseline value (average of Days 2 and 3) minus ALLN-177 treatment value (mean of Days 5, 6, and 7) divided by baseline value times 100% |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline Period to Treatment Period 24-hour Urinary Oxalate Excretion | 7 days | All Participants (N=16) completed treatment and were included in the analysis population. | mg/day | MEAN |
| SECONDARY | Percent Change From Baseline Period to Treatment Period in 24-hour Urinary Oxalate Excretion | 7 days | All Participants (N=16) were included in the analysis. | percentage change | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline Period to Treatment Period 24-hour Urinary Oxalate Excretion | ALLN-177 | -13.92 | Standard Deviation 18.37 | mg/day | |
| Percent Change From Baseline Period to Treatment Period in 24-hour Urinary Oxalate Excretion | ALLN-177 | -13.28 | Standard Deviation 16.62 | percentage change |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Baseline Period [No Treatment, 3 Days] | STARTED | ALLN-177 | 16 | |
| Baseline Period [No Treatment, 3 Days] | COMPLETED | ALLN-177 | 16 | |
| Baseline Period [No Treatment, 3 Days] | NOT COMPLETED | ALLN-177 | 0 | |
| ALLN-177 Treatment Period [4 Days] | STARTED | ALLN-177 | 16 | |
| ALLN-177 Treatment Period [4 Days] | COMPLETED | ALLN-177 | 16 | |
| ALLN-177 Treatment Period [4 Days] | NOT COMPLETED | ALLN-177 | 0 | |
| Follow up Period [4 Days] | STARTED | ALLN-177 | 16 | |
| Follow up Period [4 Days] | COMPLETED | ALLN-177 | 16 | |
| Follow up Period [4 Days] | NOT COMPLETED | ALLN-177 | 0 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal discomfort | Gastrointestinal disorders | ALLN-177 | 1 | 16 | 1 |
| other | Abdominal distension | Gastrointestinal disorders | ALLN-177 | 4 | 16 | 4 |
| other | Diarrhoea | Gastrointestinal disorders | ALLN-177 | 2 | 16 | 2 |
| other | Dyspepsia | Gastrointestinal disorders | ALLN-177 | 2 | 16 | 2 |
| other | Flatulence | Gastrointestinal disorders | ALLN-177 | 3 | 16 | 3 |
| other | Gastroesophageal reflux disease | Gastrointestinal disorders | ALLN-177 | 1 | 16 | 1 |
| other | Nausea | Gastrointestinal disorders | ALLN-177 | 3 | 16 | 3 |
| other | Headache | Nervous system disorders | ALLN-177 | 2 | 16 | 2 |
| other | Nephrolithiasis | Renal and urinary disorders | ALLN-177 | 1 | 16 | 1 |
| other | Pruritis | Skin and subcutaneous tissue disorders | ALLN-177 | 1 | 16 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | ALLN-177 | ||
| Total, other adverse events | ALLN-177 | 9 | 16 |
| Total, serious adverse events | ALLN-177 | 0 | 16 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 30783888 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02289755
GET https://conductscience.org/api/trials/v1/NCT02289755/registered